NEW ZEALAND GAZETTE

No. 163

Health

Medicines Act 1981

Classification of Medicines

Pursuant to section 106 (1) of the Medicines Act 1981, I, Tuariki John Delamere, Associate Minister of Health, hereby declare the following:

1. The medicines listed in Schedule 1 to this notice are classified as prescription medicines.

2. The medicines listed in Schedule 2 to this notice are classified as restricted medicines.

3. The medicines listed in Schedule 3 to this notice are classified as pharmacy-only medicines.

Every reference to a medicine in this notice applies whether the medicine is synthetic in origin or is from biological or mineral sources.

Unless specific reference is made otherwise, every reference applies also to medicines that are—

(a) Preparations and admixtures containing any proportion of any substance listed in the notice.

(b) Salts and esters of any substance listed in the notice.

(c) Preparations or extracts of biological materials listed in the notice.

(d) Salts or oxides of elements listed in the notice.

Where any reference is modified by a statement of the strength of the medicine, the strength is calculated using the free acid, base, alcohol or element unless specifically stated otherwise.

Schedule 1

Prescription Medicines

atorvastatin

desirudin

eformoterol

ibutilide

irinotecan

letrozole

melatonin

olanzapine

reteplase

ritonavir

ropinirole

stavudine

tacrolimus

tiludronic acid

topiramate

toremifene.

Schedule 2

Restricted Medicines

hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; in rectal medicines containing 1% or less by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of not more than 35 grams of cream or ointment per container or 12 suppositories per pack.

Schedule 3

Pharmacy-only Medicines

amethocaine: for topical use in medicines containing more than 2%

azelastine: for nasal use

etofenamate

fexofenadine

lithium: for dermatological use in medicines containing 1% or less

paracetamol: in suppositories; in liquid form; in tablet, capsule or powder form containing 500 milligrams or less and in packs containing more than 10 grams; in powder form containing more than 500 milligrams but not more than 1000 milligrams per sachet and not more than 10 grams per pack

penciclovir: for the treatment of herpes labialis.

Dated this 11th day of November 1997.

TUARIKI JOHN DELAMERE, Associate Minister of Health.

GO8356

Inland Revenue

Tax Administration Act 1994

Notice of Product Ruling

1. This is a notice of a product ruling made under section 91F of the Tax Administration Act 1994.

2. Product ruling No. 97/83 was issued on 10 November 1997. It relates to an employee share purchase scheme “General Plan”, and the application of sections BG 1, CD 5, CH 2, CH 3, EB 1, GB 1 and the “accrual rules” as defined in section OZ 1 (1) of the Income Tax Act 1994.

3. A copy of the ruling may be obtained by writing to the Assistant General Manager (Adjudication & Rulings), National Office, Inland Revenue, P.O. Box 2198, Wellington.

JEFFREY TYLER, Assistant General Manager (Adjudication & Rulings).

GO8357

Notice of Product Ruling

1. This is a notice of a product ruling made under section 91F of the Tax Administration Act 1994.

2. Product ruling No. 97/82 was issued on 10 November 1997. It relates to an employee share purchase scheme “Executive Plan”, and the application of sections BG 1, CD 5, CH 2, CH 3, EB 1, GB 1 and the “accrual rules” as defined in section OZ 1 (1) of the Income Tax Act 1994.

3. A copy of the ruling may be obtained by writing to the Assistant General Manager (Adjudication & Rulings), National Office, Inland Revenue, P.O. Box 2198, Wellington.

JEFFREY TYLER, Assistant General Manager (Adjudication & Rulings).

GO8358

Notice of Product Ruling

1. This is a notice of a product ruling made under section 91F of the Tax Administration Act 1994.

2. Product ruling No. 97/81 was issued on 10 November 1997. It relates to an employee share purchase scheme “Invitation Plan”, and the application of sections BG 1,